Efficacy of Ketamine for the Prevention of Relapse in Patients with Opioid-Use Disorders (OUD)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520843-34-00

Acronym

EXCELLENCE/0421/0543

Enrollment

Registered

2025-01-29

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use Disorder

Brief summary

Reversal of comorbid negative affective behaviors, Prolongation/maintenance of abstinence in OUD patients, Reduction in cravings

Detailed description

Identification of predictive biomarkers: (i) Emotion regulation ability; (ii) Stress response biomarkers; (iii) Changes in neural activity, Association between ketamine-induced changes in brain activity and treatment outcomes

Interventions

DRUGKETAMINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Reversal of comorbid negative affective behaviors, Prolongation/maintenance of abstinence in OUD patients, Reduction in cravings	—

Secondary

Measure	Time frame
Identification of predictive biomarkers: (i) Emotion regulation ability; (ii) Stress response biomarkers; (iii) Changes in neural activity, Association between ketamine-induced changes in brain activity and treatment outcomes	—

Countries

Cyprus

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026